Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613

NCT06848088 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT06848088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06848088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
April 14, 2025
Completion date
October 10, 2029
Enrollment
48 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma